Your browser doesn't support javascript.
Humoral Immunogenicity of 3 COVID-19 Messenger RNA Vaccine Doses in Patients With Inflammatory Bowel Disease.
Schell, Trevor L; Knutson, Keith L; Saha, Sumona; Wald, Arnold; Phan, Hiep S; Almasry, Mazen; Chun, Kelly; Grimes, Ian; Lutz, Megan; Hayney, Mary S; Farraye, Francis A; Caldera, Freddy.
  • Schell TL; Department of Medicine, University of Wisconsin School of Medicine & Public Health, Madison, WI, USA.
  • Knutson KL; Department of Immunology, Mayo Clinic Jacksonville, Jacksonville, FL, USA.
  • Saha S; Department of Medicine, Division of Gastroenterology & Hepatology, University of Wisconsin School of Medicine & Public Health, Madison, WI, USA.
  • Wald A; Department of Medicine, Division of Gastroenterology & Hepatology, University of Wisconsin School of Medicine & Public Health, Madison, WI, USA.
  • Phan HS; Department of Medicine, University of Wisconsin School of Medicine & Public Health, Madison, WI, USA.
  • Almasry M; Department of Medicine, University of Wisconsin School of Medicine & Public Health, Madison, WI, USA.
  • Chun K; Labcorp, R&D and Specialty Medicine, Burlington, NC, USA.
  • Grimes I; Department of Medicine, Division of Gastroenterology & Hepatology, University of Wisconsin School of Medicine & Public Health, Madison, WI, USA.
  • Lutz M; Department of Medicine, Division of Gastroenterology & Hepatology, University of Wisconsin School of Medicine & Public Health, Madison, WI, USA.
  • Hayney MS; School of Pharmacy, University of Wisconsin-Madison, Madison, WI, USA.
  • Farraye FA; Inflammatory Bowel Disease Center, Division of Gastroenterology & Hepatology, Mayo Clinic, Jacksonville, FL, USA.
  • Caldera F; Department of Medicine, University of Wisconsin School of Medicine & Public Health, Madison, WI, USA.
Inflamm Bowel Dis ; 28(11): 1781-1786, 2022 11 02.
Article in English | MEDLINE | ID: covidwho-1784354
Herein, we evaluated the humoral immunogenicity of a third coronavirus disease 2019 messenger RNA vaccine dose in patients with inflammatory bowel diseases. All patients displayed a humoral immune response, and median antibody concentrations were higher after the third dose than after completion of the 2-dose series.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Inflammatory Bowel Diseases / Colitis, Ulcerative / COVID-19 Type of study: Experimental Studies Topics: Vaccines Limits: Humans Language: English Journal: Inflamm Bowel Dis Journal subject: Gastroenterology Year: 2022 Document Type: Article Affiliation country: Ibd

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Inflammatory Bowel Diseases / Colitis, Ulcerative / COVID-19 Type of study: Experimental Studies Topics: Vaccines Limits: Humans Language: English Journal: Inflamm Bowel Dis Journal subject: Gastroenterology Year: 2022 Document Type: Article Affiliation country: Ibd